Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
1 finding from 1 review
Change in intensity of the nystagmus waveform · infantile nystagmus syndrome
1 finding from 1 review
Abdominal pain intensity or change in intensity · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency and intensity (measured as part of the 0‐500 point IBS‐SSS questionnaire) · people with inflammatory bowel disease
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · people with Crohn's disease
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with Crohn's disease
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with Crohn's disease
1 finding from 1 review
Abdominal pain intensity or change in intensity · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
At least 30% reduction in pain · people with Crohn's disease
It is very uncertain whether 100 mg olorinab 3 times/day changes pain intensity (30% reduction in weekly AAPS) compared with 25 mg olorinab 3 times/day (very low certainty).
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · people with inflammatory bowel disease
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · people with inflammatory bowel disease
1 finding from 1 review
Abdominal pain intensity or change in intensity · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event ‐ pain, visual analogue scale · people with inflammatory bowel disease
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · people with inflammatory bowel disease
1 finding from 1 review
Pain intensity (measure on a 0‐3 four‐point scale) · people with inflammatory bowel disease
2 findings from 1 review
Pain intensity (measure on a 0‐3 four‐point scale) · people with inflammatory bowel disease
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · people with inflammatory bowel disease
1 finding from 1 review